Zai Lab Limited

NasdaqGM:ZLAB Stock Report

Market Cap: US$3.9b

Zai Lab Past Earnings Performance

Past criteria checks 0/6

Zai Lab has been growing earnings at an average annual rate of 3.9%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 40.2% per year.

Key information

3.95%

Earnings growth rate

8.74%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate40.17%
Return on equity-31.09%
Net Margin-60.26%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%

Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%

Zai Lab Limited: Banking On Chinese Pharma Growth

May 22
author-image

New VYVGART And Pipeline Advances Will Expand Global Markets

Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 20

Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel

Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 26

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

May 14
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18
Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24
Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Jun 02
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Zai Lab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:ZLAB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25418-2522930
31 Dec 24399-2572990
30 Sep 24356-2712990
30 Jun 24323-298300-9
31 Mar 24291-3392880
31 Dec 23267-3352820
30 Sep 23263-3012710
30 Jun 23252-393269110
31 Mar 23231-4102640
31 Dec 22215-4432590
30 Sep 22197-5932570
30 Jun 22182-5292490
31 Mar 22171-5542400
31 Dec 21144-7042190
30 Sep 21115-569190-160
30 Jun 2187-537159-102
31 Mar 2161-454128-34
31 Dec 2049-2691110
30 Sep 2039-23993192
30 Jun 2029-24083185
31 Mar 2019-20174146
31 Dec 1913-195700
30 Sep 198-21258166
30 Jun 194-18145145
31 Mar 192-16033132
31 Dec 180-13922120
30 Sep 180-891474
30 Jun 180-671453
31 Mar 180-591346
31 Dec 170-501239
30 Sep 170-501041
30 Jun 170-50844
31 Mar 170-44738
31 Dec 160-38632

Quality Earnings: ZLAB is currently unprofitable.

Growing Profit Margin: ZLAB is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ZLAB is unprofitable, but has reduced losses over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare ZLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZLAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).

Return on Equity

High ROE: ZLAB has a negative Return on Equity (-31.09%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/08 18:35
End of Day Share Price 2025/07/08 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zai Lab Limited is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Louise ChenCantor Fitzgerald & Co.
Li Wang WatsekCantor Fitzgerald & Co.